One Center • One Focus • One Team

Cancer Research

Cancer Research

Breastlink is committed to working with research partners to help improve our ability to detect and treat breast cancer. Breast cancer research news from our practices

Review of the 2013 SABCS

By Nimmi Kapoor, MD and Wade Smith, MD.

Bevacizumab | 2013 SABCS | BreastlinkThe San Antonio Breast Cancer Symposium (SABCS) is an annual international conference directed towards academicians, private physicians and researchers with more than 7,000 in attendance from 90 countries. The purpose of the symposium is to relay breaking news, trial updates, advances in biology and practice-changing guidelines in breast cancer care and management.

Breastlink sends a team of physicians and researchers to SABCS every year to gather critical updates and research advances. We then disseminate the results to patients, referring physicians and the Breastlink medical team. Last year, for example, the results […]

By | February 3, 2014|Categories: Cancer News, Cancer Research|Tags: , |0 Comments

SABCS 2013 – Anastrozole

The 2013 San Antonio Breast Cancer Symposium was an engaging and invigorating event – I look forward to sharing what I have learned with colleagues and patients. If you have any specific questions you would like me to address about this year’s Symposium please feel free to leave a comment to this blog post or contact my office.

Dr. Nimmi Kapoor and I will also be sharing our observations from this year’s San Antonio Breast Cancer Symposium in a series of community lectures in January. We will share details when they are confirmed.

Here are a few observations from the plenary sessions I attended on Thursday and Friday.

Anastrozole May Provide New Option […]

By | December 17, 2013|Categories: Cancer Research, Oncology|Tags: , |0 Comments

2013 SABCS: Bisphosphonate Therapy | Anastrozole

The 2013 San Antonio Breast Cancer Symposium (SABCS) presented many studies that will change how medical professionals screen, diagnose and treat for breast cancer. The following are a few observations from the SABCS 2013 I think women and fellow medical professionals might be interested in.

Adjuvant Bisphosphonate Therapy in Breast Cancer

The meta-analysis of bisphosphonate treatment presented on Thursday will be practice changing. The Overview Analysis evaluated the benefit of bisphosphonates (such as Zometa) in all randomized trials including more than 17,000 women with breast cancer with 15-year follow-up.

Bisphosphonates given at the start of treatment to post-menopausal women with breast cancer can decrease bone recurrence by 34 percent and can significantly decrease […]

By | December 16, 2013|Categories: Cancer Research, Oncology|Tags: |0 Comments

2013 SABCS Wed. Screening & Surgical Insights

The first day of the 2013 San Antonio Breast Cancer Symposium (SABCS) featured the findings of a few breast cancer screening studies in the morning. The afternoon sessions discussed interesting results from surgical trials and updates on managing the axilla. Here are a few observations from the deliberations of Wednesday, December 11.

2013 San Antonio Breast Cancer Symposium Wednesday Morning Observations

Although the benefit of mammography on decreasing late stage cancer presentation are under question the overall decrease in breast cancer mortality is undeniable and commendable.

One study evaluated the benefit of screening MRI on average risk patients showing an increase in cancer detection in 11 women per 1000 screened. All cancers were […]

By | December 12, 2013|Categories: Breast Surgery, Cancer Research|Tags: |0 Comments

2013 SABCS Wednesday Oncology Observations

The inaugural day of the 2013 San Antonio Breast Cancer Symposium introduced new insights with treatment implications. I believe patients diagnosed with HER2-positive breast cancer(s) will find of two studies of particular interest:

NeoALTTO Trial (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization). This is an ongoing phase III clinical trial that is evaluating if a combination of trastuzumab and lapatinib (two HER2-targeted therapy agents) is better than only one of the HER2-targeted therapies. The published findings showed a moderate benefit to adding lapitinib (tykerb) to trastuzumab (herceptin) prior to surgery while significantly increasing side effects.

The same research team will present the results of the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) at the […]

By | December 12, 2013|Categories: Cancer Research, Oncology|Tags: |0 Comments

A Year in Reflection—Excited about the 2013 SABCS

A year in reflection—excited about the 2013 San Antonio Breast Cancer Symposium.

I love my job. As a breast cancer surgeon with Breastlink, I have many roles. I get to take care of patients, who, even if they don’t realize it, take care of me, too. They inspire me probably more than I can ever help them.

“It’s only cancer,” said one of my heroes, “at least I can go to a doctor and get it taken care of.” Or, “Chemo is okay. At least I can still work, a little,” said another one of my heroes. My patients often thank me, but really it is I who am quietly thanking them […]

By | December 11, 2013|Categories: Cancer Research|Tags: |0 Comments

2013 SABCS Preview

A guest blog post from Breastlink Research Development Manager Barbara Stankova.

This is an exciting time in breast cancer research and treatment. We are nearing an era where we can help patients with personalized therapies that specifically target the genetic profile of a patient’s breast cancer tumor(s). The ability to only target cancerous tumors will lead to treatment options that are far more effective – and successful – than traditional breast cancer treatment options.

One of the most motivating annual events for breast cancer advocates and researchers is the San Antonio Breast Cancer Symposium (SABCS). Not only are some of the most significant research findings announced during the five day event, it […]

By | December 10, 2013|Categories: Cancer Research|Tags: |0 Comments

San Antonio Breast Cancer Symposium – Dr. Nimmi Kapoor

San Antonio Breast Cancer Symposium Logo 2012The San Antonio Breast Cancer Symposium (SABCS) is one of the most highly esteemed breast cancer conferences in the world. This is where the updates of the most influential breast cancer trials are reported, and where breakthrough discoveries in the science of breast cancer are described. The wealth of information shared at this five-day marathon conference is enormous. I only wish I had more time to digest it all. Our understanding of breast cancer biology and treatment is continually changing, which is why the SABCS is a critical venue for anyone involved in the care of […]

By | December 21, 2012|Categories: Cancer Research|Tags: |0 Comments

San Antonio Breast Cancer Symposium – Research

Guest authors for this blog post are Kristi Maya and Barbara Stankova.

The Breastlink research had an active presence at this year’s San Antonio Breast Cancer Symposium (SABCS). The team attended presentations for the full, five-day duration of the conference. There is nothing quite like leaving San Antonio feeling refreshed and rejuvenated after connecting with some of the brightest minds seeking to find medical solutions for this and future generations of women diagnosed with breast cancer.

We hope the breast cancer community might find some of our observations of interest. Please feel free to contact us for information about Breastlink’s commitment to breast cancer research.

Breastlink Research Perspective from News Announced During the […]

By | December 10, 2012|Categories: Cancer Research|Tags: |0 Comments

San Antonio Breast Cancer Symposium 2012 – Tamoxifen

  • Although there were many meaningful announcements from the first two days of this year’s San Antonio Breast Cancer Symposium the release of a major study on adjuvant tamoxifen treatment was perhaps the most important.
  • The tamoxifen study, which gathered information from more than 6,800 women with estrogen receptor positive (ER+) breast cancer, showed a significant reduction in the reoccurrence of breast cancer.
  • This could be a noteworthy step to augment our ability to improve breast cancer survivorship – roughly 75% of breast cancers are ER+.

Background on Tamoxifen

Although tamoxifen was originally discovered in the 1960’s the US Food and Drug Administration (FDA) didn’t approve tamoxifen for the treatment […]

By | December 5, 2012|Categories: Cancer Research, Oncology|Tags: , |0 Comments
Load More Posts